Philippines - English - FDA (Food And Drug Administration)

otaner dental & medical distrinution, inc. - articaine hydrochloride , epinephrine (as bitartrate) - solution for injection (local infiltration) - 40 mg/10 mcg per ml

Philippines - English - FDA (Food And Drug Administration)

otaner dental & medical distribution, inc. - lidocaine hydrochloride , epinephrine (as bitartrate) - solution for injection (local infiltration) - 20 mg/ml (2%) / 1:80,000

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sabakem pty ltd - metsulfuron-methyl - water dispersible granule - metsulfuron-methyl urea-sulfonyl active 600.0 g/kg - herbicide - barley | cereal rye | commercial/industrial land | domestic and/or public area | flood plain | natural pasture (native) | pastur - african turnip weed | alligator weed | amsinckia | annual clovers | apple box | australian or native blackthorn | ball mustard | bellyache bush | bitou bush or boneseed | black bindweed | blackberry | blakely's red gum or gum | boggabri weed | bracken | bridal creeper | broadleaf dock | calomba daisy | cape tulip | capeweed | charlock | chickweed | chicory | climbing buckwheat | crofton weed | cutleaf mignonette | darling pea | deadnettle | denseflower fumitory | dock | erodium spp. | fennel | furze or gorse | golden dodder | great mullein | hare's-ear or treacle mustard | harrisia cactus | hawthorn | indian hedge mustard | inkweed | japanese sunflower | kangaroo thorn | lantana - lantana camara | lincoln weed, sand rocket or mustard | mallee catchfly | medic | messmate stringybark | mimosa pigra | mistflower or creeping crofton weed | narrowleaf peppermint | new zealand spinach | noogoora burr | onion or guildford grass | parthenium weed | paterson's curse | prickly lettuce | privet | ragwort | red pigweed (

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sabakem pty ltd - paraquat present as paraquat dichloride - soluble concentrate - paraquat present as paraquat dichloride pyridine-bipyridyl active 250.0 g/l - herbicide - aid to cultivation - weed control | annual clover - selective weed control | annual ryegrass - toxin minimization | banana | chi - annual grass weed | annual or wimmera ryegrass | annual ryegrass | annual weeds | anoda weed | apple-of-peru | barley grass | bellvine | blue heliotrope or blue top | broadleaf weeds | columbus grass | common morning glory | crop management | general weed - older | general weed - post-crop emergence | general weed - pre-crop emergence | general weed - pre-planting | grass weed | ground or annual ground cherry | milkweed | pre-harvest weed control | retain protein in pasture | saffron thistle | stagger weed | thornapple | total weed control | wandering jew | weed control - refer to additive label | weed seedling | wild oat | annual gooseberry | annual grasses | broadleaf grass | castor oil (false) | commelina spp. | datura ferox | datura meteloides | datura stramonium | datura tatula | false castor oil | false star thistle | field stachys | gooseberry | hedge-nettle | inter-row weed control | max. retention of protein | mexican fire plant | mint weed | physalis angulata | purple flowered thornapple | rigid rye

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dksh agrisolutions pty ltd - octyl phenol ethoxylate - liquid - octyl phenol ethoxylate emulsifiers & surfactants-noni active 1040.0 g/l - surfactant - wetting agent | spreader | surfactant - annual or wimmera ryegrass | perennial grass weed | silvergrass - aristida contorta | bunched kerosene grass | rigid ryegrass | silver grass | wimmera ryegrass | windgrass

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - solution for injection - etanercept 50 mg/ml - etanercept - etanercept - * rheumatoid arthritis:- enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate.. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. - reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* psoriatic arthritistreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x ray in patients with polyarticular symmetrical subtypes of the disease. * plaque psoriasis treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.* paediatric plaque psoriasis treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.* juvenile idiopathic arthritis- treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. - treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. enbrel has not been studied in children aged less than 2 years.* axial spondyloarthritis- ankylosing spondylitis(as)treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.- non-radiographic axial spondyloarthritistreatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids)

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - solution for injection - etanercept 50 mg/ml - etanercept - etanercept - * rheumatoid arthritis:- enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate.. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. - reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* psoriatic arthritistreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x ray in patients with polyarticular symmetrical subtypes of the disease. * plaque psoriasis treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.* paediatric plaque psoriasis treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.* juvenile idiopathic arthritis- treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. - treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.enbrel has not been studied in children aged less than 2 years.* axial spondyloarthritis- ankylosing spondylitis(as)treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.- non-radiographic axial spondyloarthritistreatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids).

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - powder and solvent for solution for injection - etanercept 25 mg/vial - etanercept - etanercept - rheumatoid arthritis:- enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. - reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* psoriatic arthritistreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x ray in patients with polyarticular symmetrical subtypes of the disease. * plaque psoriasis treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.* paediatric plaque psoriasis treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.* juvenile idiopathic arthritis- treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. - treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.- treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.*axial spondyloarthritis- ankylosing spondylitis(as)treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.- non-radiographic axial spondyloarthritistreatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids).

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

redox limited - zinc sulfate heptahydrate - topical solution/suspension - zinc sulfate heptahydrate mineral-zinc active 980.0 g/kg - dermatological preps. - goat | sheep | billy | buck | capra hircus | doe | ewe | hogget | kid | lamb | ovine | ram | weaner | wether - bacterial prevention, cleansing or disin | mycotic dermatitis | disinfecting

Australia - English - Department of Health (Therapeutic Goods Administration)

samsung bioepis au pty ltd - etanercept, quantity: 50 mg - injection, solution - excipient ingredients: water for injections; monobasic sodium phosphate monohydrate; sodium chloride; dibasic sodium phosphate heptahydrate; sucrose - adults (18 years and older),rheumatoid arthritis,active, adult rheumatoid arthritis (ra) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (dmards). brenzys can be used in combination with methotrexate. severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease.,psoriatic arthritis,the signs and symptoms of active and progressive psoriatic arthritis in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. etanercept has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.,plaque psoriasis,adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.,ankylosing spondylitis,the signs and symptoms of active ankylosing spondylitis in adults.,non-radiographic axial spondyloarthritis,treatment of adults with active* non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or mri change who have had an inadequate response to nsaids .,*active disease is defined as a bath ankylosing spondylitis disease activity index (basdai) score of greater than or equal to 4.